View all opportunities

Use the Filter Opportunities panel on the right to filter these results.

Licence for dossier usage and supply agreement.
Bortezomib 3.5mg powder for concentrate for injection [Opportunity for a buyer]
22 October 2013
Licence for dossier usage and supply agreement.
Zoledronic acid 4mg/5ml concentrate for solution for infusion [Opportunity for a buyer]
22 October 2013
Licence for dossier usage and supply agreement.
Licence for dossier usage and supply agreement.
Seeking dossiers/products for MENA region [Opportunity for a seller]
16 October 2013
Ready dossiers for pharma products with zone IV a / b stability and meeting requirements of the MENA region.
Dossiers required for EU, USA and MENA [Opportunity for a seller]
22 September 2013
We require dossiers for a broad range of medicines for the EU, USA and MENA on a non-exclusive basis.
Licensing of Oral Drug Delivery Products [Opportunity for a buyer]
19 September 2013
Athena have developed CTD dossiers on Oral Drug Delivery Products that we are looking to license out to partners who can receive products either in finished packs or bulk for local compression/encapsulation.
Ellis Pharma are the leading suppliers of global originator / innovator product to the pharmaceutical industry. Our strong manufacturer and supplier relationships allow us to access medicines on a global scale in order for you to be able to conduct the study you require.
Alternative to Invega Sustenna [Opportunity for a buyer]
31 August 2013
This is an extended release injection product that is being developed as an NDA and as an EU CTD MAA, as a low cost alternative to Invega Sustenna.
Clarithromycin XL [Opportunity for a buyer]
05 August 2013
Antibiotic.
Pioglitazone [Opportunity for a buyer]
05 August 2013
Diabetes.
Atorvastatin [Opportunity for a buyer]
05 August 2013
Cholesterol lowering.
The product is a 30-day depot formulation being developed as an EU CTD MAA and as a USA NDA 505 (b)(2) that is non-infringing.
Risperdone Injectable Depot: A Generic to Risperdal Consta [Opportunity for a buyer]
31 July 2013
This is an extended release injection product that is being developed as an ANDA and as an EU CTD MAA.
The oral dispersible tablets are available in 125mg, 250mg and 500mg strengths.
Generic glatiramer in PFS will be available to file as a USA ANDA in 2013. It is available for the EU but the licensee would have to perform clinical trials.
Octreotide LAR: A Generic to Sandostatin LAR [Opportunity for a buyer]
15 July 2013
The product is a 30-day depot formulation being developed as an EU CTD MAA.
This product is identical in every respect to Seretide Diskus. MAA was filed in the EU in 2012. It is still available for license in some countries, especially countries outside of Europe.
Biosimilar Adalimumab mAb with Phase I pK/PD in Humans [Opportunity for a buyer]
15 July 2013
This product is highly similar to Humira and is fully documented, with stability according to EU requirements; with regulatory analytics; and, proof of comparability in a phase I human study. It will complete phase III pK/PD comparative clinical studies in humans in 2013.
This once-daily generic product treats attention deficit disorder (ADHD) and is available for license outside the USA including Europe. It is manufactured in USA FDA inspected facility and launched in the USA.
This product (100 and 400mg vials) is highly similar to Avastin and is fully documented, with stability according to EU requirements; with regulatory analytics; and, proof of comparability in a phase I pK/PD comparative clinical study in humans.
This product is highly similar to MabThera and is fully documented, with stability according to EU requirements; with regulatory analytics; and, proof of comparability with phase I and phase III pK/PD comparative clinical studies in humans.
Zonisamide capsules 25mg, 50mg, 100mg [Opportunity for a buyer]
03 July 2013
Anticonvulsant
Phenytoin sodium tablets 100mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Olmesartan FC tablets, 10mg, 20mg, 40mg [Opportunity for a buyer]
03 July 2013
Hypertension
Linezolid tablets 600mg [Opportunity for a buyer]
03 July 2013
Antibiotic
Ezetimibe tablets 10mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Calcipotriol ointment 0.05% w/w [Opportunity for a buyer]
03 July 2013
Psoriasis
Atovaquone suspension 750 mg/ml [Opportunity for a buyer]
03 July 2013
Anti-Malarial
Acamprosate DR Tablets 333mg [Opportunity for a buyer]
03 July 2013
Addiction
Zolmitriptan ODT Tablets 2.5mg, 5mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Zolmitriptan Tablets 2.5mg, 5mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Voriconazole Tablets 50mg, 200mg [Opportunity for a buyer]
03 July 2013
Antifungal
Trospium Tablets 15mg, 20mg, 30mg [Opportunity for a buyer]
03 July 2013
Antispasmodic
Topiramate Tablets, 25mg, 50mg, 100mg, 200mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Telmisartan HCTZ Tablets, 40/12.5mg, 80/12.5mg, 80/25mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Telmisartan Tablets, 20mg, 40mg, 80mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Rosuvastatin Tablets 5mg, 10mg, 20mg, 40mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Ropinirole Tablets 0.25mg, 0,5mg, 1mg, 2mg, 5mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Rizatriptan ODT Tablets 5mg, 10mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Rizatriptan Tablets 5mg, 10mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Riluzole Tablets 50mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Pramipexole Tablets 0.088mg, 0.18mg, 0.35mg, 0.7mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Phenytoin Sodium capsules 25mg, 50mg, 100mg, 300mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Perindopril/Indapamide Tablets 2/0.625mg, 4/1.25mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Perindopril Tablets: 2mg, 4mg, 8mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Olanzapine ODT Tablets 5mg, 10mg, 15mg, 20mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Olanzapine Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Nebivolol Tablets 5mg, 10mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Montelukast Film Coated Tablets 10mg [Opportunity for a buyer]
03 July 2013
Respiratory
Montelukast Chewable Tablets 4mg, 5mg [Opportunity for a buyer]
03 July 2013
Respiratory
Mometasone Cream 0.1% w/w [Opportunity for a buyer]
03 July 2013
Psoriasis
Mometasone Ointment 0.1% w/w [Opportunity for a buyer]
03 July 2013
Psoriasis
Levocetirizine Tablets 5mg [Opportunity for a buyer]
03 July 2013
Antihistamine
Imiquimod Cream 5% w/w [Opportunity for a buyer]
03 July 2013
Genital Warts
Gemcitabine Injection: 200mg, 1g [Opportunity for a buyer]
03 July 2013
Oncology
Escitalopram Tablets 5mg, 10mg, 15mg, 20mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Desloratadine Tablets 5mg [Opportunity for a buyer]
03 July 2013
Antihistamine
Atovaquone/Proguanil Tablets 250/100 mg [Opportunity for a buyer]
03 July 2013
Anti-Malarial
Entacapone/ Levodopa/ Carpidopa film-coated tablets [Opportunity for a buyer]
01 May 2013
Generic to Stalevo®/ Novartis. 200mg + 50/12.5; 75/18.75; 100/25; 125/31.25; 150/37.5; 175/43.75; 200/50 mg
Vitamin D3 ATC A11CC05 [Opportunity for a buyer]
19 April 2013
Prevention and treatment of vitamin D deficiency in the elderly.
Omega 3 Acid Ethyl Esters 84% ATC C10AX06 [Opportunity for a buyer]
19 April 2013
Lipid reducers.
Nicorandil ATC C01DX16 [Opportunity for a buyer]
19 April 2013
Vasodilatory for angina treatment.
Imipenem Plus Cilastatin [Opportunity for a buyer]
19 April 2013
Antibiotic ATC J01DH51.
Aciclovir 5% Lipstick [Opportunity for a buyer]
19 April 2013
Lipstick 3g - 5% aciclovir.
Aripiprazol 5/ 10/ 15/ 30 mg tablets [Opportunity for a buyer]
23 August 2012
Generic to Abilify® ex BMS/ Otsuka
Bosentan 62.5 and 125 mg film coated tablets [Opportunity for a buyer]
23 August 2012
Generic to Tracleer®/ Roche
Tirofiban vial and bags [Opportunity for a buyer]
23 August 2012
Generic to Aggrastat®/ Iroko 50 mcg/ml – 250 ml bags infusion solution 250 mcg/ml – 50 ml vials concentrate
Eplerenone 25 and 50 mg film coated tablets [Opportunity for a buyer]
23 August 2012
Generic to Inspra®/ Pfizer. EU manufacturer.
Nicotine Chewing Gum [Opportunity for a buyer]
16 August 2012
Alkalon offers a range of finished product formulations and is seeking partnership opportunities worldwide. 2 and 4 mg available in several flavours. Our Nicotine Polacrilex Chewing Gum portfolio is based on a high quality dossier and has received MA's in several EU countries.
Biosimilar Imiglucerase [Opportunity for a buyer]
23 July 2012
Imiglucerase is a biosimilar of Genzyme’s Cerezyme®, approved for the treatment of Gaucher’s disease, the most prevalent genetic metabolic disorder caused by a deficiency of glucocerebrosidase enzyme. The only therapeutic treatment for Gaucher disease is enzyme replacement therapy. Imiglucerase is a monomeric glycoprotein with 497 amino acids and has four N-glycosylation sites expressed in CHO cells.

Filter Opportunities

Search for

Testimonials

Einar Geir Hreinsson, Vice-President Strategic Projects at Actavis, says:
"We used this channel to reach potential customers and it turned out to be considerably more effective than we had expected. It is invaluable to be able to introduce a new project like Opening Pharma in this way, through a single portal with connections in all directions. This will be our first choice the next time we want to give a new project a good promotion."

Rich DiCicco, Chief Executive Officer of Harvest Moon Pharma, comments:
"Harvest Moon Pharma has listed its complex generics and biosimilars on SourceGenerics for three years. We have received enquiries from 206 companies - including Pfizer, Sanofi, Teva, Stada, Ranbaxy and Sandoz - from 58 countries, and we are very pleased with the results. We intend to keep listing on SourceGenerics indefinitely."

Sanjiv Puri, Chief Executive Officer of Australia's Generic Partners, tells us:
"Within a week of posting our business opportunities on SourceGenerics we had received over 10 quality enquiries from leading generics companies throughout the world."

Why don't you post an opportunity or call us to see how we can help you find what you're looking for.